A study of the inconsistency of molecular typing in primary tumor and axillary lymph node metastasis of breast cancer

中国临床实用医学 Pub Date : 2017-10-25 DOI:10.3760/CMA.J.ISSN.1673-8799.2017.05.007

Xiangxin Zheng, Xiaoqing Guan, Ji Wu, Shu-cheng Gu, Xiaoling Jiang, Xiǎohóng Shí, Mu Yuan, B. Lu, X. Qiu, Xuxu Zhang

{"title":"A study of the inconsistency of molecular typing in primary tumor and axillary lymph node metastasis of breast cancer","authors":"Xiangxin Zheng, Xiaoqing Guan, Ji Wu, Shu-cheng Gu, Xiaoling Jiang, Xiǎohóng Shí, Mu Yuan, B. Lu, X. Qiu, Xuxu Zhang","doi":"10.3760/CMA.J.ISSN.1673-8799.2017.05.007","DOIUrl":null,"url":null,"abstract":"Objective \nTo investigate the value of molecular typing in primary tumor and axillary lymph node metastasis of breast cancer. \n \n \nMethods \nA total of 428 cases of female patients with unilateral breast cancer with axillary lymph node metastasis were selected from January 2011 to January 2016.ER, PR, Her-2 and Ki67 were detected by immunohistochemistry in primary tumor and axillary lymph node metastasis. \n \n \nResults \nMolecular typing of primary tumor and axillary lymph node metastases was inconsistent in 31 patients (31/428), luminal A of primary tumors in 14 cases, luminal B of primary tumors in 10 cases, while 4 cases of Her-2 over-expression and 3 cases of triple negative breast cancer in axillary lymph node metastases. \n \n \nConclusion \nThere was an inconsistency in primary tumor and axillary lymph node metastasis of some breast cancer.Immunohistochemistry for primary tumor and axillary lymph node metastasis of breast cancer associated with axillary lymph node metastasis should routinely carried out.Based on molecular typing of primary tumor and axillary lymph node metastasis to develop individualized treatment programs, patients could benefit from it. \n \n \nKey words: \nBreast cancer; Primary focus; Axillary lymph node metastasis; Molecular typing; Chemotherapy; Hormonal therapy","PeriodicalId":64135,"journal":{"name":"中国临床实用医学","volume":"8 1","pages":"26-29"},"PeriodicalIF":0.0000,"publicationDate":"2017-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国临床实用医学","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1673-8799.2017.05.007","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Objective To investigate the value of molecular typing in primary tumor and axillary lymph node metastasis of breast cancer. Methods A total of 428 cases of female patients with unilateral breast cancer with axillary lymph node metastasis were selected from January 2011 to January 2016.ER, PR, Her-2 and Ki67 were detected by immunohistochemistry in primary tumor and axillary lymph node metastasis. Results Molecular typing of primary tumor and axillary lymph node metastases was inconsistent in 31 patients (31/428), luminal A of primary tumors in 14 cases, luminal B of primary tumors in 10 cases, while 4 cases of Her-2 over-expression and 3 cases of triple negative breast cancer in axillary lymph node metastases. Conclusion There was an inconsistency in primary tumor and axillary lymph node metastasis of some breast cancer.Immunohistochemistry for primary tumor and axillary lymph node metastasis of breast cancer associated with axillary lymph node metastasis should routinely carried out.Based on molecular typing of primary tumor and axillary lymph node metastasis to develop individualized treatment programs, patients could benefit from it. Key words: Breast cancer; Primary focus; Axillary lymph node metastasis; Molecular typing; Chemotherapy; Hormonal therapy

查看原文本刊更多论文

乳腺癌原发肿瘤与腋窝淋巴结转移的分子分型不一致性研究

目的探讨分子分型在乳腺癌原发肿瘤及腋窝淋巴结转移中的价值。方法选取2011年1月至2016年1月收治的女性单侧乳腺癌伴腋窝淋巴结转移患者428例。免疫组化法检测原发肿瘤和腋窝淋巴结转移灶中ER、PR、Her-2和Ki67的表达。结果31例(31/428)患者原发肿瘤与腋窝淋巴结转移灶分子分型不一致，原发肿瘤腔内A 14例，原发肿瘤腔内B 10例，腋窝淋巴结转移灶中Her-2过表达4例，三阴性3例。结论部分乳腺癌的原发肿瘤与腋窝淋巴结转移不一致。乳腺癌伴腋窝淋巴结转移的原发肿瘤和腋窝淋巴结转移应常规进行免疫组化检查。根据原发肿瘤和腋窝淋巴结转移的分子分型，制定个体化治疗方案，使患者受益。关键词:乳腺癌;主要的焦点;腋窝淋巴结转移;分子类型;化疗;激素治疗

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

中国临床实用医学

自引率

0.00%

发文量

6167